National registry data presented by European physicians at last month’s EuroPCR provided the latest boon to adoption of transcatheter aortic valve implantation (TAVI). The encouraging results revealed high success rates in addition to acceptable mortality rates and complications in the high-risk patient population considered in the registries.
Through 2014, rapid adoption of TAVI across Europe will result from the highly underpenetrated patient population. Like other percutaneous heart valve therapies, the use of TAVI will be mostly reserved for high-risk patients, such as those considered in these registries, who currently go untreated because their conditions are too advanced to risk the highly invasive tissue or mechanical heart valve replacement options. However, the new technique will also penetrate the market for these more conventional methods, especially among older patients who would benefit from the less invasive procedures.
Because this presentation will feature major report findings, it is ONLY available to purchasers of the following publication:
European Markets for Heart Valve Devices 2010
Click here to request more information about this webinar and find out how to attend.
This webinar, presented by MRG Analyst Dan Whalen, will answer the following questions:
- What support does the latest clinical research provide for TAVI?
- To what extent will TAVI penetrate the diagnosed, untreated high-risk patient population?
- How much will TAVI take away from surgical heart valve replacement volumes?
- What strategies have Edwards Lifesciences and Medtronic employed in this market?
- What are emerging competitors doing differently?
Registration
Targeting TAVI – Understanding the Uptake of Transcatheter Aortic Valve Implantation in Europe
Because this webinar will feature major report findings, it is ONLY available to purchasers of the following report:
European Markets for Heart Valve Devices 2010
For more information about purchasing this report and registering for this webinar, contact us at tfletcher@mrg.net
The webinar will take place on Wednesday, June 30 at 11:00 am US Eastern Time, 8:00 am US Pacific Time, 5:00 pm Central European Time (Paris).
Contact Us
Tyler Fletcher
416-364-7776 x 166
tfletcher@mrg.net
|
|
|
Webinar Details
Date & Time
Wednesday, June 30, 2010
11:00 a.m. EDT
8:00 am US Pacific Time
5:00 pm Central European Time
|
|
Duration
30 Minutes |
|
|
|
About the Speaker:
Dan Whalen is a Senior Analyst in the Cardiovascular group, as well as author of European Markets for Heart Valve Devices 2010. Dan has also written and overseen the production of several other related reports on such topics as interventional cardiology, cardiac rhythm management devices and electrophysiology mapping and ablation catheters.
| |
